Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Villalona-Calero

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2002
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activityY Xu, M A Villalona-Calero
Clinical Pharmacology and Therapeutics|January 15, 2014
Race and ethnicity in cancer therapy: what have we learned?C Grenade, M A Phelps, M A Villalona-Calero
The American Journal of the Medical Sciences|May 1, 1989
Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDSM A Villalona-Calero, S S Schrem, K R Phelps
Medical and Pediatric Oncology|January 1, 1992
Management of testicular seminoma following organ transplantationM A Villalona-Calero, T Ducker, M Holasek, et al.
Biochemical and Biophysical Research Communications|December 29, 2009
An epigenetic mechanism for capecitabine resistance in mesotheliomaK V Kosuri, X Wu, L Wang, et al.
American Journal of Clinical Oncology|August 1, 1992
Extragonadal abdominal germ cell cancersJ L Gonzalez-Vela, M A Villalona-Calero, J L Torkelson, et al.
Biotechniques|July 26, 2002
RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal modelW Duan, H Ding, W G Zhu, et al.
Investigational New Drugs|July 22, 2005
A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumorsG A Otterson, J Lavelle, M A Villalona-Calero, et al.
Oncogene|December 26, 2001
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cellsW G Zhu, Z Dai, H Ding, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignanciesY Xu, J M Kolesar, L J Schaaf, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2002
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activityY Xu, M A Villalona-Calero
Clinical Pharmacology and Therapeutics|January 15, 2014
Race and ethnicity in cancer therapy: what have we learned?C Grenade, M A Phelps, M A Villalona-Calero
The American Journal of the Medical Sciences|May 1, 1989
Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDSM A Villalona-Calero, S S Schrem, K R Phelps
Medical and Pediatric Oncology|January 1, 1992
Management of testicular seminoma following organ transplantationM A Villalona-Calero, T Ducker, M Holasek, et al.
Biochemical and Biophysical Research Communications|December 29, 2009
An epigenetic mechanism for capecitabine resistance in mesotheliomaK V Kosuri, X Wu, L Wang, et al.
American Journal of Clinical Oncology|August 1, 1992
Extragonadal abdominal germ cell cancersJ L Gonzalez-Vela, M A Villalona-Calero, J L Torkelson, et al.
Biotechniques|July 26, 2002
RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal modelW Duan, H Ding, W G Zhu, et al.
Investigational New Drugs|July 22, 2005
A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumorsG A Otterson, J Lavelle, M A Villalona-Calero, et al.
Oncogene|December 26, 2001
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cellsW G Zhu, Z Dai, H Ding, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignanciesY Xu, J M Kolesar, L J Schaaf, et al.
Pageof 3